Correction to: Arthritis Res Ther
https://doi.org/10.1186/s13075-019-1843-9
Following publication of the original article [1], the authors reported an error in the spelling of Lorenzo Dagna’s name. The authors apologise for the error.
Incorrect spelling:
Loreno Dagna
Correct spelling:
Lorenzo Dagna
The original article [1] has been updated.
Reference
Cavalli, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther. 2019;21:54 https://doi.org/10.1186/s13075-019-1843-9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Cavalli, G., Tomelleri, A., De Luca, G. et al. Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther 21, 69 (2019). https://doi.org/10.1186/s13075-019-1850-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13075-019-1850-x